Results From the Phase 3 ElevAATe Clinical Trial in Alpha-1 Antitrypsin Deficiency by Madaline Spencer| Published on: Jun 19, 2026

Results From the Phase 3 ElevAATe Clinical Trial in Alpha-1 Antitrypsin Deficiency by Madaline Spencer| Published on: Jun 19, 2026 Alaa Hamed, MD, Global Head of Medical Affairs Rare Diseases at Sanofi, discusses results from the phase 2 ElevAATe clinical trial of efdoralprin alfa in patients with alpha-1 antitrypsin deficiency (AATD). https://checkrare.com/results-from-the-phase-3-elevaate-clinical-trial-in-alpha-1-antitrypsin-deficiency/